| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10008819 | Annals of Allergy, Asthma & Immunology | 2005 | 7 Pages |
Abstract
Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treated atopic asthmatic patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Tom C. MA, MB, BChir, Daniel K.C. MD, Melissa R. BMSc, Brian J. MD,